Silvia Calabuig‐Fariñas

Universitat de València — Spain

Medicine · Health Sciences

30h-index2.8kcitations199works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(34), Cancer Genomics and Diagnostics(34), Sarcoma Diagnosis and Treatment(33), Cancer Immunotherapy and Biomarkers(26), Cancer Cells and Metastasis(21)

Publications199 total

Tissue and peripheral T cell receptor repertoire predicts immunotherapy response and progression-free survival in NSCLC patients
Scientific Reports·2025Open Access
Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations
npj Precision Oncology·2025Open Access
Clinical Utility of Soluble Immune Mediators and cfDNA in Endometrial Cancer
The Journal of Liquid Biopsy·2025Open Access
Circulating immune signatures as predictors of immunotherapy response in non-small cell lung cancer
The Journal of Liquid Biopsy·2025Open Access
EP.06.77 Exploring the Impact of Peripheral Immune Landscape on Immunotherapy Outcomes in Non-Small Cell Lung Cancer
Journal of Thoracic Oncology·2025
NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC
Cancer Letters·2025Open Access
High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models
Nature Communications·2025· 4 citedOpen Access
Estudio de la señalización inducida por la interacción hormona-receptor a través de animaciones: un enfoque interdisciplinar en Ingeniería Biomédica
2025Open Access
La inteligencia artificial en la universidad: una revolución que enriquece el aprendizaje crítico
2025Open Access
Targeted delivery of therapeutics to metastatic lung cancer cells using aptamer-conjugated nanoemulsions
Journal of Controlled Release·2025· 1 citedOpen Access
Abstract P4-08-04: Selective activity of rogaratinib in PIK3CA- and ESR1-wild-type, FGFR1/2-amplified hormone receptor-positive breast cancer (HR+/HER2- BC): a co-clinical trial
Clinical Cancer Research·2025
Circulating Immune Population As A Prognostic And Predictive Tool In Patients With Endometrial Cancer
International Journal of Gynecological Cancer·2025
Cross-Method Comparison for Braf P.V600 Mutation Cfdna Testing in Melanoma: Brafi Study
SSRN Electronic Journal·2025Open Access
Cross-Method Comparison for Braf P.V600 Mutation Cfdna Testing in Melanoma: Brafi Study
SSRN Electronic Journal·2025Open Access
Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI study
EJC Skin Cancer·2025Open Access
Diagnostic and Prognostic Value of Angiogenic Status in Hereditary Hemorrhagic Telangiectasia
Diagnostics·2024Open Access
G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1
Cell Death and Disease·2024· 10 citedOpen Access
NSCLC exosomes: Unlocking biomarker potential
The Journal of Liquid Biopsy·2024Open Access
BRAF V600 mutations detection in melanoma: A cross-methodological study using CFDNA
The Journal of Liquid Biopsy·2024Open Access
A first-line approach: Liquid biopsy-guided osimertinib therapy for EGFR-mutated NSCLC
The Journal of Liquid Biopsy·2024Open Access
page 1 of 10Next →

Frequent Co-authors

Eloísa Jantus‐Lewintre(26), Carlos Camps(22), Rafael Sirera(12), Ana Blasco(12), Antonio Llombart‐Bosch(10), José Antonio López‐Guerrero(9), Javier Martín‐Broto(7), Antonio Pellı́n(7), Alejandro Herreros‐Pomares(6), Susana Torres‐Martínez(6), Andrea Moreno‐Manuel(6), Antònia Obrador‐Hevia(6), Rafael Ramos(5), E. Durendez-Saez(5), R. Guijarro(5), Isidro Machado(5), Macarena Ferrero(5), Miguel Martorell(4), Regina Alemany(4), Marina Meri-Abad(4)